肠道菌群与动脉粥样硬化及中药干预现状  

Research status on gut microbiota and atherosclerosis and treatment with Chinese medicine

作　　者：高风 郭丽君 丁砚秋 任高灿 付双清 马晓昌[1,2] GAO Feng;GUO Lijun;DING Yanqiu;REN Gaocan;FU Shuangqing;MA Xiaochang(Xiyuan Hospital of China Academy of Chinese Medical Sciences,Beijing 100091,China;National Clinical Research Center for Chinese Medicine Cardiology,Beijing 100091,China;Graduate School of Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]中国中医科学院西苑医院,北京100091 [2]国家中医心血管病临床医学研究中心,北京100091 [3]北京中医药大学研究生院,北京100029

出　　处：《中华中医药杂志》2025年第2期775-779,共5页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家重点研发计划(No.2018YFC1707404)。

摘　　要：动脉粥样硬化是一种伴有脂质代谢紊乱的慢性低级别炎症性疾病,是心血管疾病的共同病理基础。近年来,肠道微生物群被认为是一个重要的宿主“器官”,可能与包括心血管疾病和代谢综合征在内的许多代谢紊乱相关的疾病的发病机制密切相关。基于中医“心-肠”理论,调节肠道菌群及其代谢产物或可成为辨证论治动脉粥样硬化的重要切入点。文章就肠道菌群与动脉粥样硬化关系、肠道菌群失调影响动脉粥样硬化发生发展的相关机制,以及中药有效成分和中药复方对动脉粥样硬化的干预作用进行了综述,以期为中医药抗动脉粥样硬化研究提供借鉴和方向。Atherosclerosis is a chronic low-grade inflammatory disease accompanied by the dysregulation of lipid metabolism,which is a common pathological basis of cardiovascular diseases(CVDs).In recent years,gut microbiota has been regarded as an important host'organ',which might be closely related to the pathogenesis of many metabolic disorders,including cardiovascular diseases and metabolic syndrome.Based on the‘heart-gut'theory of traditional Chinese medicine,the regulation of gut microbiota and its metabolites may be an important entry point for the identification and treatment of atherosclerosis.This review aims to explain the relationship between gut microbiota and atherosclerosis,the relevant mechanisms by which dysbiosis of gut microbiota affects the development of atherosclerosis,and the interventional effects of active ingredients of Chinese medicine and Chinese herbal compound prescriptions on atherosclerosis,with a view to providing reference and direction for anti-atherosclerosis research in traditional Chinese medicine.

关 键 词：肠道菌群 动脉粥样硬化 中医药 研究进展 

分 类 号：R259[医药卫生—中西医结合]